Lion Point Capital LP Has $424,000 Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)

Lion Point Capital LP lifted its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 11.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 36,250 shares of the biotechnology company’s stock after buying an additional 3,750 shares during the period. REGENXBIO comprises approximately 0.8% of Lion Point Capital LP’s investment portfolio, making the stock its 17th biggest position. Lion Point Capital LP owned approximately 0.07% of REGENXBIO worth $424,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its holdings in REGENXBIO by 0.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 327,451 shares of the biotechnology company’s stock worth $5,878,000 after purchasing an additional 1,683 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of REGENXBIO by 2.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,226,957 shares of the biotechnology company’s stock worth $22,025,000 after purchasing an additional 34,385 shares during the last quarter. Perceptive Advisors LLC acquired a new position in shares of REGENXBIO in the fourth quarter valued at approximately $6,146,000. Virtu Financial LLC bought a new position in REGENXBIO in the 4th quarter valued at approximately $377,000. Finally, PNC Financial Services Group Inc. boosted its position in REGENXBIO by 73.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock worth $32,000 after buying an additional 746 shares during the period. 88.08% of the stock is currently owned by institutional investors.

Insider Transactions at REGENXBIO

In related news, Director Kenneth T. Mills sold 2,210 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $13.77, for a total value of $30,431.70. Following the completion of the sale, the director now directly owns 408,035 shares of the company’s stock, valued at approximately $5,618,641.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other REGENXBIO news, Director Kenneth T. Mills sold 12,221 shares of the firm’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $13.78, for a total value of $168,405.38. Following the transaction, the director now directly owns 408,035 shares of the company’s stock, valued at $5,622,722.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kenneth T. Mills sold 2,210 shares of REGENXBIO stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $13.77, for a total transaction of $30,431.70. Following the transaction, the director now owns 408,035 shares of the company’s stock, valued at $5,618,641.95. The disclosure for this sale can be found here. Insiders have sold 65,279 shares of company stock valued at $875,634 in the last 90 days. 13.13% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $39.00 price target on shares of REGENXBIO in a research report on Wednesday, September 4th. The Goldman Sachs Group began coverage on REGENXBIO in a report on Friday, June 7th. They set a “buy” rating and a $38.00 target price on the stock. Barclays decreased their price target on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Finally, StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, REGENXBIO presently has an average rating of “Moderate Buy” and an average target price of $37.91.

REGENXBIO Stock Performance

Shares of RGNX opened at $10.68 on Friday. The firm has a market cap of $526.05 million, a PE ratio of -1.82 and a beta of 1.22. REGENXBIO Inc. has a 52-week low of $10.49 and a 52-week high of $28.80. The business’s 50 day moving average price is $12.35 and its two-hundred day moving average price is $14.72.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.24. The business had revenue of $22.30 million for the quarter, compared to analyst estimates of $22.97 million. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. REGENXBIO’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.66) earnings per share. Research analysts predict that REGENXBIO Inc. will post -4.66 EPS for the current fiscal year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.